Insulin formulation to treat intestinal malabsorption

Elgan Pharma is a biotech company focused on developing innovative therapies for preterm infants, addressing critical medical challenges faced by this vulnerable population. Their lead product, ELGN-GI, has shown significant promise in enhancing gastrointestinal maturation and function, which is crucial for achieving nutritional independence in premature infants. This therapy not only accelerates the maturation process but also minimizes complications associated with feeding and digestion, which are common in preterm births.

Another key product, ELGN-EYE, targets the prevention of vision impairment caused by retinopathy of prematurity (ROP). This therapy works by promoting normal retinal development while simultaneously reducing inflammation and oxidative stress, which are significant contributors to vision problems in premature infants. Through these advanced therapeutic solutions, Elgan Pharma aims to improve the health outcomes and quality of life for newborns at risk, addressing unmet medical needs in the field of neonatology.

Israel

We named our company ELGAN Pharma, as we are dedicated to improving outcome for babies who are Extremely Low Gestational Age Newborns (ELGANs). This means they are born more than 3 months before term. 

​

Premature birth is the number one cause of newborn deaths. With improved standard-of-care worldwide, survival rate increases, leading to the need of improving outcome and quality of life.   

​

 

ELGAN Pharma is a neonatology-focused biotechnology company, dedicated to developing safe tailored therapies to address medical problems and developmental difficulties that are common in babies born very early.

Elgan Pharma

Company Details